Literature DB >> 2894851

Heparin cofactor II: cDNA sequence, chromosome localization, restriction fragment length polymorphism, and expression in Escherichia coli.

M A Blinder1, J C Marasa, C H Reynolds, L L Deaven, D M Tollefsen.   

Abstract

Heparin cofactor II (HCII) is an inhibitor of thrombin in plasma that is activated by dermatan sulfate or heparin. An apparently full-length cDNA for HCII was isolated from a human liver lambda gt11 cDNA library. The cDNA consisted of 2215 base pairs (bp), including an open-reading frame of 1525 bp, a stop codon, a 3'-noncoding region of 654 bp, and a poly(A) tail. The deduced amino acid sequence contained a signal peptide of 19 amino acid residues and a mature protein of 480 amino acids. The sequence of HCII demonstrated homology with antithrombin III and other members of the alpha 1-antitrypsin superfamily. Blot hybridization of an HCII probe to DNA isolated from sorted human chromosomes indicated that the HCII gene is located on chromosome 22. Twenty human leukocyte DNA samples were digested with EcoRI, PstI, HindIII, KpnI, or BamHI, and Southern blots of the digests were probed with HCII cDNA fragments. A restriction fragment length polymorphism was identified with BamHI. A slightly truncated form of the cDNA, coding for Met-Ala instead of the N-terminal 18 amino acids of mature HCII, was cloned into the vector pKK233-2 and expressed in Escherichia coli. The resultant protein of apparent molecular weight 54,000 was identified on an immunoblot with 125I-labeled anti-HCII antibodies. The recombinant HCII formed a complex with 125I-thrombin in a reaction that required the presence of heparin or dermatan sulfate.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894851     DOI: 10.1021/bi00402a039

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli.

Authors:  Suryakala Sarilla; Sally Y Habib; Douglas M Tollefsen; David B Friedman; Diana R Arnett; Ingrid M Verhamme
Journal:  Anal Biochem       Date:  2010-07-27       Impact factor: 3.365

Review 2.  New biological concepts on coagulation inhibitors.

Authors:  N Sala; J Fontcuberta; M L Rutllant
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

Review 3.  Glycosaminoglycans and the regulation of blood coagulation.

Authors:  M C Bourin; U Lindahl
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

4.  Interaction of thrombin with antithrombin, heparin cofactor II, and protein C inhibitor.

Authors:  H C Whinna; F C Church
Journal:  J Protein Chem       Date:  1993-12

5.  Molecular characterization of antithrombin III (ATIII) variants using polymerase chain reaction. Identification of the ATIII Charleville as an Ala 384 Pro mutation.

Authors:  P Molho-Sabatier; M Aiach; I Gaillard; J N Fiessinger; A M Fischer; G Chadeuf; E Clauser
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

6.  The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand.

Authors:  Amanda J Boyle; Leigh Ann Roddick; Varsha Bhakta; Melissa D Lambourne; Murray S Junop; Patricia C Liaw; Jeffrey I Weitz; William P Sheffield
Journal:  BMC Biochem       Date:  2013-03-07       Impact factor: 4.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.